Current Issue: April 2024
Case Study Series
Case Study Series: Improving Outcomes in Pediatric NTRK Gene Fusion-Positive Solid Tumors: Importance of Genomic Testing and Targeted Therapy With the TRK Inhibitor Larotrectinib
In the Clinic: Case Studies Let us begin our discussion with 2 pediatric cases that prompt the question, “How will you proceed?” Patient 1: A baby […]
Feature Article
Immune Checkpoint Inhibitor Therapy in Locally Advanced MSI GI Malignancies
Abstract: Locally advanced gastrointestinal (GI) malignancies have conventionally been treated in a multimodal fashion that combines (neo)adjuvant chemotherapy with or without radiation and definitive surgical resection. […]
Feature Article
Increasing Inclusion and Equity for Black Women in Breast Cancer Clinical Trials
Abstract: Black women diagnosed with breast cancer experience a disproportionately high mortality rate. The disparity in outcomes between Black and White women is multifactorial, with a […]
Advances in LLM
The Development of Menin Inhibitors in AML and ALL
H&O What are menin inhibitors, and how do they function in the context of acute myeloid leukemia/acute lymphoblastic leukemia? GI Menin inhibitors are a new form […]
Advances in Drug Development
PROTAC Drugs in Cancer Care
H&O What are PROTACs, and how do they target proteins in cancer treatment? PF Proteolysis-targeting chimeras (PROTACs) are a new class of drugs that, in my […]
Colorectal Cancer
Liver Transplant in Patients With Metastatic Colorectal Cancer
H&O How common are liver-limited metastases in colorectal cancer (CRC)? BA Approximately one-third of patients with metastatic CRC (mCRC) have metastases that are isolated to the […]
Feature Article
The Role of Noncovalent BTK Inhibitors in the Era of Covalent BTK Inhibitors
Abstract: Despite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some […]
Feature Article
Immunotherapy in the Treatment of Advanced or Recurrent Endometrial Cancer
Abstract: The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical […]
Letter From the Editor
Letter From the Editor: Empty Nest
Spring is here, which means graduation time, among other things. My youngest daughter is about to graduate from college and will be home briefly for the […]
Highlights
Highlights in Prostate Cancer From the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
January 25-27, 2024 • San Francisco, California and Virtual Abiraterone Plus Olaparib Improves Outcomes in Metastatic Castration-Resistant Prostate Cancer A combination of abiraterone and olaparib (Lynparza, […]
Advances in Hematology
Thrombotic Complications of Influenza and COVID-19 Infections
H&O How often do influenza and COVID-19 lead to thrombotic complications? PN The true incidence of thrombotic complications with influenza and COVID-19 is unclear. A study […]
Advances in Drug Development
Coordination Between the FDA and the US Patent and Trademark Office
H&O What is the Executive Order on Promoting Competition in the American Economy and how does it relate to coordination between the FDA and the USPTO? […]
CLL
Six-Year Update of the ELEVATE-TN Study on Acalabrutinib
H&O Could you describe the impetus for and design of the ELEVATE-TN trial? JS The ELEVATE-TN study was conducted to seek regulatory authorization for acalabrutinib (Calquence, […]